RIDGEFIELD, Conn., May 16, 2012 /PRNewswire/ -- Boehringer Ingelheim will present results from LUX-Lung 3, the company's pivotal Phase III clinical trial investigating afatinib in patients

WALTHAM, Mass., April 30, 2012 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a late-stage oncology company focused on the clinical development

AUSTIN, Texas, April 26, 2012 /PRNewswire/ -- A clinical trial has demonstrated that Oncoprex® (TUSC2 nanoparticles) can be safely administered in advanced lung cancer patients to halt

BOULDER, Colo., April 20, 2012 /PRNewswire/ -- Results from the combined analysis of two European Phase II trials were presented today at the 3rd European Lung Cancer Conference in Geneva, Switzerland.

Patients with advanced non-small cell lung cancer should only receive treatment with the drug erlotinib before receiving standard chemotherapy if their tumor is known to harbor EGFR mutations, researchers report at the 3rd European Lung Cancer Conference in Geneva, Switzerland.